Company intelligence / Profile preview
Coeptis Pharmaceuticals
Pittsburgh, Pennsylvania, United Statescoeptistx.com ↗
- Ownership
- Public · ZSQR
- Development stage
- Other
01
Overview
DVX-201 (unmodified NK cells) in Phase 1 for relapsed/refractory AML/high-risk MDS (enrolling, no DLTs at dose level 900M, LPLV expected 2Q24); completed Phase 1 for acute viral respiratory diseases. Preclinical programs in SNAP-CAR NK/T and CD38-GEAR-NK.
- Therapeutic areas
- OncologyInfectious DiseasesHematologyImmunology
- Modalities
- Cell therapyNatural killer cell therapyCAR-T cell therapyGene-edited cell therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Deverra TherapeuticsUniversity of PittsburghVyGen-BioFred Hutch Cancer CenterDuke Cancer InstituteNovant Health
04
Financials
- Market cap
- $177.6M
- Total revenue
- $1.4M
- Enterprise value
- $162.1M
Beyond the preview
Go deeper on Coeptis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coeptis Pharmaceuticals.